206 related articles for article (PubMed ID: 27411790)
21. p53-regulated GML gene expression in non-small cell lung cancer. a promising relationship to cisplatin chemosensitivity.
Higashiyama M; Miyoshi Y; Kodama K; Yokouchi H; Takami K; Nishijima M; Nakayama T; Kobayashi H; Minamigawa K; Nakamura Y
Eur J Cancer; 2000 Mar; 36(4):489-95. PubMed ID: 10717525
[TBL] [Abstract][Full Text] [Related]
22. Silencing TRIM29 Sensitizes Non-small Cell Lung Cancer Cells to Anlotinib by Promoting Apoptosis
Wu M; Jin MM; Cao XH; Zhao L; Li YH
Curr Cancer Drug Targets; 2024; 24(4):445-454. PubMed ID: 37644752
[TBL] [Abstract][Full Text] [Related]
23. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) correlates with cisplatin resistance in human non-small cell lung cancer xenografts.
Nakagawa T; Inoue Y; Kodama H; Yamazaki H; Kawai K; Suemizu H; Masuda R; Iwazaki M; Yamada S; Ueyama Y; Inoue H; Nakamura M
Oncol Rep; 2008 Aug; 20(2):265-70. PubMed ID: 18636185
[TBL] [Abstract][Full Text] [Related]
24. Preparation and cytotoxicity of cisplatin-containing liposomes.
Carvalho Júnior AD; Vieira FP; Melo VJ; Lopes MT; Silveira JN; Ramaldes GA; Garnier-Suillerot A; Pereira-Maia EC; Oliveira MC
Braz J Med Biol Res; 2007 Aug; 40(8):1149-57. PubMed ID: 17665053
[TBL] [Abstract][Full Text] [Related]
25. Intracellular accumulation of thallium as a marker of cisplatin cytotoxicity in nonsmall cell lung carcinoma: an application of inductively coupled plasma mass spectrometry.
Hanada T; Isobe H; Saito T; Ogura S; Takekawa H; Yamazaki K; Tokuchi Y; Kawakami Y
Cancer; 1998 Sep; 83(5):930-5. PubMed ID: 9731897
[TBL] [Abstract][Full Text] [Related]
26. Trichostatin A sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinase.
Wu J; Hu CP; Gu QH; Li YP; Song M
Acta Pharmacol Sin; 2010 Jan; 31(1):93-101. PubMed ID: 20048748
[TBL] [Abstract][Full Text] [Related]
27. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).
Ohmori T; Morikage T; Sugimoto Y; Fujiwara Y; Kasahara K; Nishio K; Ohta S; Sasaki Y; Takahashi T; Saijo N
Jpn J Cancer Res; 1993 Jan; 84(1):83-92. PubMed ID: 8383649
[TBL] [Abstract][Full Text] [Related]
28. ARRB1 enhances the chemosensitivity of lung cancer through the mediation of DNA damage response.
Shen H; Wang L; Zhang J; Dong W; Zhang T; Ni Y; Cao H; Wang K; Li Y; Wang Y; Du J
Oncol Rep; 2017 Feb; 37(2):761-767. PubMed ID: 28035404
[TBL] [Abstract][Full Text] [Related]
29. The human lung cancer drug resistance-related gene BC006151 regulates chemosensitivity in H446/CDDP cells.
Li S; Shi H; Ji F; Wang B; Feng Q; Feng X; Jia Z; Zhao Q; Qian G
Biol Pharm Bull; 2010; 33(8):1285-90. PubMed ID: 20686220
[TBL] [Abstract][Full Text] [Related]
30. Non-cross resistance of ZD0473 in acquired cisplatin-resistant lung cancer cell lines.
Kawamura-Akiyama Y; Kusaba H; Kanzawa F; Tamura T; Saijo N; Nishio K
Lung Cancer; 2002 Oct; 38(1):43-50. PubMed ID: 12367792
[TBL] [Abstract][Full Text] [Related]
31. USP3 promotes cisplatin resistance in non-small cell lung cancer cells by suppressing ACOT7-regulated ferroptosis.
Tao R; Liu Z; Zhang Z; Zhang Z
Anticancer Drugs; 2024 Jul; 35(6):483-491. PubMed ID: 38502867
[TBL] [Abstract][Full Text] [Related]
32. Role and mechanism of COL3A1 in regulating the growth, metastasis, and drug sensitivity in cisplatin-resistant non-small cell lung cancer cells.
Ren J; Zhao S; Lai J
Cancer Biol Ther; 2024 Dec; 25(1):2328382. PubMed ID: 38530094
[TBL] [Abstract][Full Text] [Related]
33. [RNA Interference targeting GRP75 decreases cisplatin resistance in human lung adenocarcinoma cell].
Shi S; He Z; Cai J; Qiu J
Zhongguo Fei Ai Za Zhi; 2011 Apr; 14(4):305-10. PubMed ID: 21496427
[TBL] [Abstract][Full Text] [Related]
34. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer.
Oliver TG; Mercer KL; Sayles LC; Burke JR; Mendus D; Lovejoy KS; Cheng MH; Subramanian A; Mu D; Powers S; Crowley D; Bronson RT; Whittaker CA; Bhutkar A; Lippard SJ; Golub T; Thomale J; Jacks T; Sweet-Cordero EA
Genes Dev; 2010 Apr; 24(8):837-52. PubMed ID: 20395368
[TBL] [Abstract][Full Text] [Related]
35. Association of p73 G4C14-to-A4T14 polymorphism at exon 2 with the response of human lung adenocarcinoma cell lines to chemotherapy.
Liu K; Jiang L; Zhou X
Cell Biol Int; 2010 Jan; 34(2):185-8. PubMed ID: 19947923
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of cisplatin sensitivity and platinum uptake by 40 degrees C hyperthermia in resistant cells.
Ohtsubo T; Saito H; Tanaka N; Matsumoto H; Sugimoto C; Saito T; Hayashi S; Kano E
Cancer Lett; 1997 Oct; 119(1):47-52. PubMed ID: 18372521
[TBL] [Abstract][Full Text] [Related]
37. Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.
Sasaki Y; Shinkai T; Eguchi K; Tamura T; Ohe Y; Ohmori T; Saijo N
Cancer Chemother Pharmacol; 1991; 27(4):263-70. PubMed ID: 1847845
[TBL] [Abstract][Full Text] [Related]
38. Modulation of sensitivity to cis-diamminedichloroplatinum (II) by thromboxane A2 receptor antagonists in non-small-cell lung cancer cell lines.
Kasahara K; Fujimura M; Bando T; Shibata K; Shirasaki H; Matsuda T
Br J Cancer; 1996 Nov; 74(10):1553-8. PubMed ID: 8932334
[TBL] [Abstract][Full Text] [Related]
39. Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells.
Hettinga JV; Lemstra W; Meijer C; Dam WA; Uges DR; Konings AW; De Vries EG; Kampinga HH
Br J Cancer; 1997; 75(12):1735-43. PubMed ID: 9192975
[TBL] [Abstract][Full Text] [Related]
40. XAF1 overexpression inhibits the malignant progression and cisplatin resistance of NSCLC by activating endoplasmic reticulum stress.
Chen B; Cheng Y; Wu H; Yao J
Mol Biol Rep; 2024 Mar; 51(1):435. PubMed ID: 38520543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
